PASG
Passage Bio, Inc. Common Stock
stockNASDAQ
passage bio, inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (cns) diseases. the company develops pbgm01, which utilizes a proprietary, aavhu68 capsid to deliver to the brain and peripheral tissues a functional glb1 gene encoding lysosomal acid beta-galactosidase (ã-gal) for infantile gm1; pbft02, which utilizes an aav1 capsid to deliver to the brain a functional granulin, or grn, gene encoding progranulin for the treatment of ftd caused by a deficiency of progranulin; and pbkr03, which utilizes a proprietary, aavhu68 capsid to deliver to the brain and peripheral tissues a functional galc gene encoding the hydrolytic enzyme galactosylceramidase, for infantile krabbe disease. it has a strategic research collaboration with the trustees of the university of pennsylvania's gene therapy program; and collaboration agreement, and a development services and clinical supply agreement with catalent maryland, inc. the company was fou
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 4.68 | 2026-09-28 | -11.77% | -0.387 |
| 1M | 4.65 | 2026-09-04 | -11.29% | 0.614 |
| 3M | 4.70 | 2026-07-06 | -12.23% | 0.707 |
| 6M | 8.76 | 2026-04-06 | -52.91% | 1.712 |
| 1Y | 7.95 | 2025-10-03 | -48.11% | 2.676 |
| 2Y | 12.98 | 2024-10-04 | -68.22% | — |
| 5Y | 196.20 | 2021-10-04 | -97.90% | 1.651 |
Passage Bio, Inc. Common Stock (NASDAQ:PASG) stock price today is $4.13, and today's volume is 17,049. PASG is down 1.809% today. The 30 day average volume is 25,981. PASG market cap is $13.27M with 3.22M shares outstanding.